MacroGenics

MacroGenics, Inc. is a biopharmaceutical company focused on discovering and developing antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops new therapeutic product candidates using its antibody-based technology platforms and also in partnership with other biopharmaceutical companies. The Company has a pipeline of product candidates in human clinical testing, primarily against various cancers. These include two product candidates developed using Fc Optimization platform, namely margetuximab, an antibody for the treatment of certain types of metastatic breast cancers and gastroesophageal cancers, and MGA271, an antibody to impact various tumors through multiple potential mechanisms of action. In addition, the Company has created different product candidates based on Dual-Affinity Re-Targetingr (DART) platform.
Type
Public
HQ
Rockville, US
Employees
269 (est)
MacroGenics has headquartered in Rockville, US

Key People at MacroGenics

Heather Preston

Heather Preston

Observer of Boards
Scott Koenig

Scott Koenig

President & Chief Executive Officer and Board Member
Ezio Bonvini

Ezio Bonvini

Senior Vice President, Research
Eric Risser

Eric Risser

Vice President, Development
James Karrels

James Karrels

Vice President, Chief Financial Officer
Lynn Cilinski

Lynn Cilinski

Vice President, Controller and Treasurer

MacroGenics Locations

Rockville, US
South San Francisco, US
Rockville, US

MacroGenics Metrics

MacroGenics Summary

Market capitalization

$943 M

Closing share price

$26.3
MacroGenics's latest market capitalization is $943 M.

MacroGenics Market Value History

MacroGenics Company Life

You may also be interested in